Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDLR mRNA exosome therapy for homozygous familial hypercholesterolemia
ChiCTR2100050939Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Sep 2021
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Low Density Lipoprotein Receptor mRNA exosomes in homozygous familial hypercholesterolemia (HoFH), sponsored by Tangdu Hospital. Primary endpoints: Low-density lipoprotein cholesterol, Safety and tolerability and 2 more. Started Sep 2021; status: recruiting.
02
Drugs
Low Density Lipoprotein Receptor mRNA exosomes
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on ChiCTR2100050939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050939.